ID: ALA3318073

Max Phase: Preclinical

Molecular Formula: C19H21N5O4

Molecular Weight: 383.41

Molecule Type: Small molecule

Representations

Canonical SMILES:  COc1cc(C(=O)n2nc(Nc3ccc(C)cc3)nc2N)cc(OC)c1OC

Standard InChI:  InChI=1S/C19H21N5O4/c1-11-5-7-13(8-6-11)21-19-22-18(20)24(23-19)17(25)12-9-14(26-2)16(28-4)15(10-12)27-3/h5-10H,1-4H3,(H3,20,21,22,23)

Standard InChI Key:  JEUKFJYLKNNCEE-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 383.41

Molecular Weight (Monoisotopic): 383.1594

AlogP: 2.63

#Rotatable Bonds: 6

Polar Surface Area: 113.52

Molecular Species: NEUTRAL

HBA: 9

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 9

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 11.02

CX Basic pKa:

CX LogP: 3.43

CX LogD: 3.43

Aromatic Rings: 3

Heavy Atoms: 28

QED Weighted: 0.67

Np Likeness Score: -0.96

References

1. Romagnoli R, Baraldi PG, Salvador MK, Prencipe F, Bertolasi V, Cancellieri M, Brancale A, Hamel E, Castagliuolo I, Consolaro F, Porcù E, Basso G, Viola G..  (2014)  Synthesis, antimitotic and antivascular activity of 1-(3',4',5'-trimethoxybenzoyl)-3-arylamino-5-amino-1,2,4-triazoles.,  57  (15): [PMID:25025853] [10.1021/jm5008193]

Source

Source(1):

• Scientific Literature